Drugs / Progenta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01069094 | Jul 2004 → Jan 2005 | leiomyoma | Repros Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Progenta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01069094 ↗ |
| Route | Oral | “administered as a once daily oral dose for 90 days.” NCT01069094 ↗ |